



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

August 12, 2025

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

BSE CODE: 543329

NSE SYMBOL: WINDLAS

Dear Sir/ Madam.

Sub: Press Release

Please find attached herewith press release on Windlas Biotech Limited Reports its Q1 and FY26 Financial Results.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

Ananta Narayan Panda
Company Secretary & Compliance Officer

Encl: as above

Press Release

Windlas Biotech Limited Reports its Q1FY26 Financial Results

- ✓ 10th successive quarter of record revenue
- ✓ Revenue Rs. 210 Cr., YoY growth of 20%
- ✓ EBITDA Rs. 27 Cr., YoY growth of 27%
- ✓ PBT Rs 23 Cr. YoY growth 27%
- ✓ PAT Rs 18 Cr. YoY growth 31%
- ✓ EPS stood at Rs. 8.4 YoY growth 30%

Tuesday, 12th August 2025, Gurugram: Windlas Biotech Limited, one of the leading players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India, reported its unaudited financials for the quarter ended June 30, 2025.

Consolidated Highlights –**Q1FY26 Highlights:**

- **Revenue from operations** stood at Rs. 210.1 crores as against Rs. 175.2 crores, a growth of 19.9% YoY.
- **EBITDA** stood at Rs. 26.5 crores as against Rs. 20.9 crores, a growth of 27.0% YoY. **EBITDA Margin (%)** came in at 12.6%.
- **PAT** stood at Rs. 17.7 crores as against Rs.13.5 crore, a growth of 31.1% YoY. **PAT Margin (%)** came in at 8.4%.

Vertical Performance Update

Particulars (In Rs. Crores)	Q1FY26	Q1FY25	YoY
Generic Formulations CDMO	160.2	135.9	18%
Trade Generics & Institutional	43.9	35.1	25%
Exports	6.0	4.1	45%

Generic Formulations CDMO Vertical Highlights

- Q1FY26 revenue for the CDMO vertical stood at Rs. 160.2 crores, up 18% YoY.
- CDMO vertical contributed approximately 76% to the consolidated revenue.

Trade Generics & Institutional Vertical Highlights

- Q1FY26 revenue for the Trade Generics & Institutional vertical stood at Rs. 43.9 crores, up 25% YoY.
- Trade Generics vertical contributed approximately 21% to the consolidated revenue.

Exports Vertical Highlights

- Q1FY26 revenue for the revenue for the Exports vertical stood at Rs. 6.0 crores, up 45% YoY.
- Exports vertical contributed approximately 3% to the consolidated revenue.

Commenting on the results Mr. Hitesh Windlass, Managing Director – Windlas Biotech said, *“This quarter reinforces our strong growth trajectory, marking the tenth successive quarter of record revenue performance. The Company reported an earnings per share (EPS) of Rs. 8.4 for Q1 FY26, marking a 30% YoY increase. In line with its commitment to shareholder value creation, the Board paid a dividend of Rs 12.2 Cr (Rs 5.8 per share) to its shareholders for FY25 in August 2025.*

The Indian Pharmaceutical Market (IPM) registered a YoY growth of 9% in Q1FY26, with a modest volume growth of 1%. We delivered 19.9% YoY revenue growth for the quarter, driven by steady contributions from all three business verticals.

Our Generic Formulations CDMO vertical continues to deliver healthy performance, driven by customer additions, expansion in product portfolio, and consistent delivery of quality manufacturing products. The Trade Generics and Institutional vertical sustained their growth momentum through deeper penetration across core and adjacent markets, supported by government healthcare schemes such as Ayushman Bharat and Jan Aushadhi. In exports, we are actively pursuing several strategic initiatives aimed at meeting the increasing global demand for high-quality and affordable generic medicines.

On the manufacturing front, we are strengthening our operational infrastructure through the upgrade of our recently acquired Plant 6, which remains on schedule for its planned capacity expansion. Additionally, our injectable facility is enhancing our ability to serve diverse customer needs and deliver a wider range of products efficiently.

As we move ahead, our outlook on the broader Indian pharmaceutical sector remains optimistic. Our focus remains on driving long-term value for shareholders by boosting operational efficiencies, nurturing key talent, and expanding our dosage form capabilities.”

Adding further, Ms. Komal Gupta, CEO & CFO - Windlas Biotech said, *“On the back of performance momentum seen consecutively across last ten quarters, we delivered another quarter of consistent performance with revenue of Rs. 210 Cr., EBITDA Rs 27 Cr. and PAT Rs 18 Cr. The company recorded 20% YoY growth in revenue, 27% in EBITDA and 31% in PAT. The company’s gross margin expanded by 71 bps YoY to 38.3%, while EBITDA margin improved by 70 bps to 12.6%.*

Windlas Biotech is strategically focused on strengthening core capabilities and expanding into high-potential geographies to meet evolving market needs. Through disciplined execution and operational efficiency, we are well-positioned to drive sustainable growth, enhance competitiveness, and create long-term value for our shareholders.

Our Generic Formulations CDMO vertical achieved growth of 17.8% YoY, contributing Rs. 160 crore in revenue. Our continuous endeavor to ensure delivery excellence and stringent quality standards strengthen our positioning as a trusted CDMO partner in the pharmaceutical industry. The Trade Generics and Institutional vertical grew by 25.2% YoY to Rs. 44 crore. This growth was driven by

enhanced distribution reach, stronger market presence in previously under-served regions and increased product range. Exports vertical registered 45.4% YoY growth to Rs. 6 crore, as we continue to deepen our presence in key regulated and semi-regulated markets.

As we progress through FY26, the company remains focused on driving process enhancements and strengthening internal efficiencies. We are currently witnessing encouraging trends across all business verticals. Backed by a differentiated value proposition and strong customer engagement, the company is optimally structured to unlock its long-term goals in a sustainable and impactful manner.”

About Windlas Biotech Limited

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information please contact:



Windlas Biotech Limited

CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: Komal@windlasbiotech.com

Contact no.: +91 124 2821034



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Parin Narichania / Ms. Drashti Shah

Email: parin.n@sgapl.net / drashti.shah@sgapl.net

Contact no.: +91 9930025733 / +91 8767224443